Schulte-Sasse U, Hess W, Markschies-Hornung A, Tarnow J
Anesth Analg. 1984 Sep;63(9):791-8.
The interaction of halothane anesthesia and intravenous verapamil (0.15 mg/kg over 10 min) was investigated in eight patients scheduled for coronary artery bypass surgery. All patients had a normal left ventricular (LV) function at rest and were on chronic beta-blocker therapy. Halothane produced a marked reduction in mean arterial pressure (MAP), cardiac index, and in LV contractility as documented by a decrease in LV peak positive dP/dt. Verapamil caused an additional depression (16%) of LV peak positive dP/dt accompanied by a small increase (3 mm Hg) in LV end-diastolic pressure. The combined negative inotropic propensities of halothane and verapamil did not produce any overt untoward effects even in the presence of chronic low dose beta-blocker therapy. The predominant hemodynamic effect of verapamil was a systemic vasodilation resulting in a further reduction in MAP (12%) while heart rate remained unaffected. Despite reducing myocardial oxygen demand, caution must be exercised in dose selection in each drug to avoid regional myocardial ischemia due to the combined hypotensive effects of halothane and verapamil.
对八名计划进行冠状动脉搭桥手术的患者研究了氟烷麻醉与静脉注射维拉帕米(10分钟内注射0.15毫克/千克)之间的相互作用。所有患者静息时左心室(LV)功能正常,且正在接受慢性β受体阻滞剂治疗。氟烷使平均动脉压(MAP)、心脏指数以及LV收缩力显著降低,LV峰值正向dP/dt降低证明了这一点。维拉帕米使LV峰值正向dP/dt进一步降低(16%),同时LV舒张末期压力小幅升高(3毫米汞柱)。即使在慢性低剂量β受体阻滞剂治疗的情况下,氟烷和维拉帕米联合的负性肌力倾向也未产生任何明显的不良影响。维拉帕米的主要血流动力学效应是全身血管舒张,导致MAP进一步降低(12%),而心率未受影响。尽管降低了心肌需氧量,但在每种药物的剂量选择上必须谨慎,以避免由于氟烷和维拉帕米联合的降压作用导致局部心肌缺血。